Medical Cannabis Studies


• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)


• batten-disease (6)

• benefits (9)

• breast-cancer (7)


• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)


• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)


• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)


• fibromyalgia (2)

• fibrosis (1)


• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)


• health-care (1)

• hiv (7)

• huntingtons-disease (1)


• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)


• krabbe-disease (4)


• liver (2)

• lung-cancer (2)

• lupus (1)


• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)


• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)


• pain (29)

• pancreatitis (1)

• prostate-cancer (2)


• schizophrenia (2)

• skin (1)

• sports (3)


• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo (2009)

    It is demonstrated that phytocannabinoids have important therapeutic properties, and specifically cannabidiol or CBD has anticonvulsant properties in animal models which highlights its potential as a new antiepileptic drug. View study

  • Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro (2007)

    It has been shown that Cannabidiol, a non-psychoactive component of cannabis, has low affinity for cannabinoid receptors CB1 and CB2, and in this study the first evidence is shown that it can also show the inverse agonism of the CB2 receptor. What can contribute to its documented anti-inflammatory properties. View study

  • Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (2012)

    CBD is a component of cannabis that moderately inhibits the degradation of endocannabinoid anandamide. These results indicate that the inhibition of the deactivation of anandamide contributes to the antipsychotic effects of CBD, which could suggest a novel mechanism in the treatment of schizophrenia. View study

  • Cannabidiol Enhances the Inhibitory Effects of ?9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival (2010)

    Adding cannabidiol to ?9-THC may improve the effectiveness of ?9-THC in the treatment of glioblastoma in patients with cancer. When treating the cells with both compounds it was observed that these acted synergistically to inhibit cell proliferation. View study

  • Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures (2012)

    In this study, cannabidiol is evidenced as a strong candidate to treat human epilepsies, since it reduces the severity of seizures. View study

  • Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes (2014)

    A study that demonstrates the potential of CBD as a promising therapeutic agent for the treatment of acne vulgaris, due to its anti-inflammatory, lipostatic and antiproliferative effects. View study

  • Cannabidiol for the treatment of psychosis in Parkinson's disease (2008)

    One of the biggest challenges faced by doctors against Parkinson’s disease is the treatment of psychosis, which is why the treatment with CBD has been suggested due to its antipsychotic and neuroprotective effects. In this study, its efficacy was evaluated and demonstrated. View study

  • Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice (2010)

    The present study suggests that cannabidiol restores liver function, normalizes levels of 5-hydroxytryptamine (5-HT) and improves brain pathology according to the normalization of brain function. Therefore, the effects of cannabidiol can result from a combination of its actions in the liver and brain. View study

  • Cannabidiol in Anxiety and Sleep: A Large Case Series. (2019)

    The objective of the present study was to determine if cannabidiol (CBD) helps to improve sleep and / or anxiety in a clinical population. It was concluded that cannabidiol may be beneficial for anxiety-related disorders. Controlled clinical studies are needed. View study

  • Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial (2018)

    The Lennox-Gastaut syndrome is a severe form of epileptic encephalopathy resistant to conventional treatments. It has been shown that cannabidiol is effective for the treatment of patients with gout attacks associated with Lennox-Gastaut syndrome and is generally well tolerated. View study

  • Cannabidiol Inhibits Cancer Cell Invasion Via Upregulation Of Tissue Inhibitor Of Matrix Metalloproteinases-1 (2011)

    Based on the results of this study, there is evidence to suggest that cannabidiol (CBD) could be used for the treatment of highly invasive cancers. View study

  • Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma�Associated Herpesvirus Infected Endothelium (2012)

    Cannabidiol has properties that inhibit the expression of the herpesvirus receptor associated with Kaposi’s sarcoma, which leads to taking cannabidiol under clinical consideration for the treatment of Kaposi’s sarcoma. View study

  • Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism (2005)

    The results of this investigation reinforced the evidence of the antitumor properties of cannabidiol (CBD) and also demonstrated its ability to limit tumor invasion. View study

  • Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1 (2012)

    Cannabinoids have the property of inhibiting the invasion of cancer cells by inducing the intercellular adhesion molecule-1 (ICAM-1), which in turn confers the induction of the tissue inhibitor of matrix metallo-proteinases-1 (TIMP-1). View study

  • Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice (2011)

    The cannabidiol (CBD) is, potentially, a safe and effective alternative for alleviating neuroinflammation and neurodegeneration. CBD ameliorates clinical signs of experimental autoimmune encephalomyelitis in mice, immunized against myelin oligodendrocyte glycoprotein. Suppression of microglial activity and T�cell proliferation by CBD appeared to contribute to these beneficial effects. View study

  • Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor (no year)

    This study was made based on the hypothesis that cannabidiol can inhibit the activity of cannabinoid agonists through the negative allosteric modulation of CB1. The results of this study showed that cannabidiol behaved as a non-competitive allosteric modulator of CB1.The allosteric modulation, together with the effects that are not CB1, can show the in vivo effects of cannabidiol. The allosteric modulators of CB1 have the potential to treat the central nervous system and peripheral disorders, while avoiding the adverse effects associated with orthosteric agonism or CB1 antagonism. View study

  • Cannabidiol is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19 (2012)

    Through this research the inhibitory effect of cannabidiol (CBD) on the catalytic activity of cytochrome P450 2C19 (CYP2C19) was studied. In this study it was demonstrated that CBD caused a potent inhibition of CYP2C19, in which a phenolic hydroxyl group Free and the pentyl side chain of the CBD can perform important functions. View study

  • Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors (2006)

    This review seeks to verify if cannabidiol is an allosteric modulator in mu and delta opioid receptors. This study showed that cannabidiol is an allosteric modulator in mu and delta opioid receptors. This property is shared by THC but not by rimonabant.10 ?M View study

  • Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure (2016)

    In the chronic phase of epilepsy, post-treatment with cannabidiol could be considered as a protection mechanism of the temporal lobe, which improves the induction of the cellular autophagy pathway and antioxidant defense. View study

  • Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis (2014)

    This research was based on studying the effects of cannabidiol (CBD) in a well-established mouse model of cardiotoxicity-induced cardiomyopathy (DOX). View study

  • Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy (2014)

    Cannabidiol prevents acute hepatic steatosis induced by alcohol in mice. The effective prevention of hepatic steatosis avoids the progressive damage caused by alcohol in the liver. View study

  • Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors (2013)

    This study results highlight the anti-inflammatory effects of cannabidiol in this viral model of multiple sclerosis and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component. View study

  • Cannabidiol Reduces A?-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPAR? Involvement (2011)

    Based on the research carried out on rats in this study, it was possible to observe in the results that blocking the peroxisome proliferator-activated receptor-c (PPARc), could significantly reduce the effects of CBD on reactive gliosis and on damage neuronal Also due to its interaction in PPARc, it was observed that CBD stimulates hippocampal neurogenesis. View study

  • Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis (2012)

    The descriptive results showed that the prolonged treatment with 10 mg / kg of cannabidiol administered to Wistar rats prevented the deterioration of memory in rats with pneumococcal meningitis. Also, it was confirmed that cannabidiol has anti-inflammatory effects in pneumococcal meningitis and prevents cognitive sequelae. View study